MR imaging of hypervascular liver masses: A review of current techniques

Radiographics

Volumn 29, Issue 2, 2009, Pages 385-402

  Silva, Alvin C ^a   Evans, James M ^a   McCullough, Ann E ^a   Jatoi, Mashal A ^a   Vargas, Hugo E ^a   Hara, Amy K ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER ASSISTED DIAGNOSIS; HEMANGIOMA; HUMAN; IMAGE ENHANCEMENT; LIVER; LIVER TUMOR; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REVIEW; VASCULARIZATION;

HEMANGIOMA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOVASCULARIZATION, PATHOLOGIC;

EID: 66149139493     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.292085123     Document Type: Article

References (61)

1. Semelka RC, Armao DM, Elias J Jr, Huda W. Imaging strategies to reduce the risk of radiation in CT studies, including selective substitution with MRI. J Magn Reson Imaging 2007;25(5):900-909.
2. Semelka RC, Martin DR, Balci C, Lance T. Focal liver lesions: comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. J Magn Reson Imaging 2001;13(3):397-401.
3. Vassiliades VG, Foley WD, Alarcon J, et al. Hepatic metastases: CT versus MR imaging at 1.5T. Gastrointest Radiol 1991;16(2):159-163.
4. Larson RE, Semelka RC, Bagley AS, Molina PL, Brown ED, Lee JK. Hypervascular malignant liver lesions: comparison of various MR imaging pulse sequences and dynamic CT. Radiology 1994;192 (2):393-399.
5. Parikh T, Drew SJ, Lee VS, et al. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 2008; 246(3):812-822.
6. Numminen K, Halavaara J, Isoniemi H, et al. Magnetic resonance imaging of the liver: true fast imaging with steady state free precession sequence facilitates rapid and reliable distinction between hepatic hemangiomas and liver malignancies. J Comput Assist Tomogr 2003;27(4):571-576.
7. Morana G, Salviato E, Guarise A. Contrast agents for hepatic MRI. Cancer Imaging 2007;7(spec no A):S24-S27.
8. Karhunen PJ. Benign hepatic tumours and tumour like conditions in men. J Clin Pathol 1986;39(2): 183-188.
9. Kim T, Federle MP, Baron RL, Peterson MS, Kawamori Y. Discrimination of small hepatic hemangiomas from hypervascular malignant tumors smaller than 3 cm with three-phase helical CT. Radiology 2001;219(3):699-706.
10. Leslie DF, Johnson CD, Johnson CM, Ilstrup DM, Harmsen WS. Distinction between cavernous hemangiomas of the liver and hepatic metastases on CT: value of contrast enhancement patterns. AJR Am J Roentgenol 1995;164(3):625-629.
11. Quinn SF, Benjamin GG. Hepatic cavernous hemangiomas: simple diagnostic sign with dynamic bolus CT. Radiology 1992;182(2):545-548.
12. Semelka RC, Brown ED, Ascher SM, et al. Hepatic hemangiomas: a multi-institutional study of appearance on T2-weighted and serial gadoliniumenhanced gradient-echo MR images. Radiology 1994;192(2):401-406.
13. Pirovano G, Vanzulli A, Marti-Bonmati L, et al. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. AJR Am J Roentgenol 2000;175(4):1111-1120.
14. Wanless IR, Mawdsley C, Adams R. On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology 1985;5(6):1194-1200.
15. Chun Hsee L, McCall JL, Koea JB. Focal nodular hyperplasia: what are the indications for resection? HPB (Oxford) 2005;7(4):298-302.
16. Nguyen BN, Flejou JF, Terris B, Belghiti J, Degott C. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 1999;23(12):1441-1454.
17. Terminology of nodular hepatocellular lesions. International Working Party. Hepatology 1995;22(3): 983-993.
18. Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005;236(1):166-177.
19. Buetow PC, Pantongrag-Brown L, Buck JL, Ros PR, Goodman ZD. Focal nodular hyperplasia of the liver: radiologic-pathologic correlation. RadioGraphics 1996;16(2):369-388.
20. Hussain SM, Terkivatan T, Zondervan PE, et al. Focal nodular hyperplasia: findings at state-of-theart MR imaging, US, CT, and pathologic analysis. RadioGraphics 2004;24(1):3-17.
21. Lizardi-Cervera J, Cuellar-Gamboa L, MotolaKuba D. Focal nodular hyperplasia and hepatic adenoma: a review. Ann Hepatol 2006;5(3):206-211.
22. Gokhale R, Whitington PF. Hepatic adenomatosis in an adolescent. J Pediatr Gastroenterol Nutr 1996;23(4):482-486.
23. Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A. Hepatic adenomas: imaging and pathologic findings. RadioGraphics 2001;21(4): 877-892.
24. Chiche L, Dao T, Salamé E, et al. Liver adenomatosis: reappraisal, diagnosis, and surgical management-eight new cases and review of the literature. Ann Surg 2000;231(1):74-81.
25. Choi BY, Nguyen MH. The diagnosis and management of benign hepatic tumors. J Clin Gastroenterol 2005;39(5):401-412.
26. Prasad SR, Wang H, Rosas H, et al. Fat-containing lesions of the liver: radiologic-pathologic correlation. RadioGraphics 2005;25(2):321-331.
27. Elsayes KM, Narra VR, Yin Y, Mukundan G, Lammle M, Brown JJ. Focal hepatic lesions: diagnostic value of enhancement pattern approach with contrast-enhanced 3D gradient-echo MR imaging. RadioGraphics 2005;25(5):1299-1320.
28. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005;19(1):3-23.
29. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 suppl 1):S35-S50.
30. Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 2002;225(1):143-149.
31. Honda H, Tajima T, Kajiyama K, et al. Vascular changes in hepatocellular carcinoma: correlation of radiologic and pathologic findings. AJR Am J Roentgenol 1999;173(5):1213-1217.
32. Efremidis SC, Hytiroglou P. The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation. Eur Radiol 2002;12(4):753-764.
33. Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001;233 (5):652-659.
34. Shinmura R, Matsui O, Kobayashi S, et al. Cirrhotic nodules: association between MR imaging signal intensity and intranodular blood supply. Radiology 2005;237(2):512-519.
35. Matsui O, Kadoya M, Kameyama T, et al. Adenomatous hyperplastic nodules in the cirrhotic liver: differentiation from hepatocellular carcinoma with MR imaging. Radiology 1989;173(1):123-126.
36. Kim YK, Lee YH, Kim CS, Han YM. Added diagnostic value of T2-weighted MR imaging to gadolinium-enhanced three-dimensional dynamic MR imaging for the detection of small hepatocellular carcinomas. Eur J Radiol 2008;67(2):304-310.
37. Xu H, Li X, Xie JX, Yang ZH, Wang B. Diffusionweighted magnetic resonance imaging of focal hepatic nodules in an experimental hepatocellular carcinoma rat model. Acad Radiol 2007;14(3): 279-286.
38. Hussain SM, Zondervan PE, Ijzermans JN, Schalm SW, de Man RA, Krestin GP. Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. RadioGraphics 2002;22(5): 1023-1036.
39. Lencioni R, Cioni D, Della Pina C, Crocetti L, Bartolozzi C. Imaging diagnosis. Semin Liver Dis 2005;25(2):162-170.
40. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42(5):1208-1236.
41. Kadoya M, Matsui O, Takashima T, Nonomura A. Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. Radiology 1992;183(3):819-825.
42. Lim JH, Choi D, Park CK, Lee WJ, Lim HK. Encapsulated hepatocellular carcinoma: CT-pathologic correlations. Eur Radiol 2006;16(10):2326-2333.
43. Rha SE, Lee MG, Lee YS, et al. Nodular regenerative hyperplasia of the liver in Budd-Chiari syndrome: CT and MR features. Abdom Imaging 2000; 25(3):255-258.
44. Al-Mukhaizeem KA, Rosenberg A, Sherker AH. Nodular regenerative hyperplasia of the liver: an under-recognized cause of portal hypertension in hematological disorders. Am J Hematol 2004;75(4): 225-230.
45. Yutani C, Imakita M, Ishibashi-Ueda H, Okubo S, Naito M, Kunieda T. Nodular regenerative hyperplasia of the liver associated with primary pulmonary hypertension. Hum Pathol 1988;19(6): 726-731.
46. Brancatelli G, Federle MP, Grazioli L, Golfieri R, Lencioni R. Benign regenerative nodules in BuddChiari syndrome and other vascular disorders of the liver: radiologic-pathologic and clinical correlation. RadioGraphics 2002;22(4):847-862.
47. Cazals-Hatem D, Vilgrain V, Genin P, et al. Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: a study in 17 explanted livers. Hepatology 2003;37(3):510-519.
48. Kondo F, Nagao T, Sato T, et al. Etiological analysis of focal nodular hyperplasia of the liver, with emphasis on similar abnormal vasculatures to nodular regenerative hyperplasia and idiopathic portal hypertension. Pathol Res Pract 1998;194(7):487-495.
49. Ros PR, Taylor HM. Malignant tumors of the liver. In: Gore RM, Levine MS, eds. Textbook of gastrointestinal radiology. 2nd ed. Philadelphia, Pa: Saunders, 2000; 1523-1568.
50. Namasivayam S, Martin DR, Saini S. Imaging of liver metastases: MRI. Cancer Imaging 2007;7:2-9.
51. Kelekis NL, Semelka RC, Woosley JT. Malignant lesions of the liver with high signal intensity on T1-weighted MR images. J Magn Reson Imaging 1996;6(2):291-294.
52. Semelka RC, Custodio CM, Cem Balci N, Woosley JT. Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. J Magn Reson Imaging 2000;11(2):141-148.
53. Sohn J, Siegelman E, Osiason A. Unusual patterns of hepatic steatosis caused by the local effect of insulin revealed on chemical shift MR imaging. AJR Am J Roentgenol 2001;176(2):471-474.
54. Danet IM, Semelka RC, Leonardou P, et al. Spectrum of MRI appearances of untreated metastases of the liver. AJR Am J Roentgenol 2003;181(3): 809-817.
55. Nasu K, Kuroki Y, Nawano S, et al. Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 2006;239(1):122-130.
56. Low RN. Abdominal MRI advances in the detection of liver tumours and characterisation. Lancet Oncol 2007;8(6):525-535.
57. Mahfouz AE, Hamm B, Wolf KJ. Peripheral washout: a sign of malignancy on dynamic gadoliniumenhanced MR images of focal liver lesions. Radiology 1994;190(1):49-52.
58. Kim YK, Lee JM, Kim CS. Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 2004;14(1): 5-13.
59. Kim YK, Lee JM, Kim CS, Chung GH, Kim CY, Kim IH. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 2005;15(2):220-228.
60. Semelka RC, Worawattanakul S, Noone TC, et al. Chemotherapy-treated liver metastases mimicking hemangiomas on MR images. Abdom Imaging 1999;24(4):378-382.
61. Colagrande S, Centi N, Galdiero R, Ragozzino A. Transient hepatic intensity differences. II. Those not associated with focal lesions. AJR Am J Roentgenol 2007;188(1):160-166.